Abstract
Opiate substitution therapies have largely contributed to improving outcomes in opiate dependent patients. Their impact has significantly diminished HIV transmission rates, decreased incidence of overdose and reduced delinquency due to heroin trafficking. Since then, some advances have been made in the formulations and dosing regimen of these treatments. They have also largely facilitated opiate withdrawal. However, concerning the maintenance of opiate abstinence, very few new treatments have been proposed. Despite considerable advances in our knowledge of the neurobiological mechanisms of opiate dependence, few clinical trials have been proposed to test new molecules both in accompanying opiate substitution and in maintaining abstinence from illicit opiate use. The objective of this article is to examine the evidence concerning the treatment of opiate dependent patients, especially new treatments and to examine the eventual gaps between currently knowledge, available treatment and demands.
Keywords: Opiate substitution treatment, opiate withdrawal, methadone, buprenorphine, naltrexone, lofexidine, clonidine, Opiate, delinquency, illicit, psychotherapy, fibrillation, enantiomers, arrhythmias, morphine, psychiatric, psychoactive, benzodiazepines
Current Pharmaceutical Design
Title: Pharmacological Treatments of Opiate Dependence
Volume: 17 Issue: 14
Author(s): Amine Benyamina, Michel Reynaud, Lisa Blecha and Laurent Karila
Affiliation:
Keywords: Opiate substitution treatment, opiate withdrawal, methadone, buprenorphine, naltrexone, lofexidine, clonidine, Opiate, delinquency, illicit, psychotherapy, fibrillation, enantiomers, arrhythmias, morphine, psychiatric, psychoactive, benzodiazepines
Abstract: Opiate substitution therapies have largely contributed to improving outcomes in opiate dependent patients. Their impact has significantly diminished HIV transmission rates, decreased incidence of overdose and reduced delinquency due to heroin trafficking. Since then, some advances have been made in the formulations and dosing regimen of these treatments. They have also largely facilitated opiate withdrawal. However, concerning the maintenance of opiate abstinence, very few new treatments have been proposed. Despite considerable advances in our knowledge of the neurobiological mechanisms of opiate dependence, few clinical trials have been proposed to test new molecules both in accompanying opiate substitution and in maintaining abstinence from illicit opiate use. The objective of this article is to examine the evidence concerning the treatment of opiate dependent patients, especially new treatments and to examine the eventual gaps between currently knowledge, available treatment and demands.
Export Options
About this article
Cite this article as:
Benyamina Amine, Reynaud Michel, Blecha Lisa and Karila Laurent, Pharmacological Treatments of Opiate Dependence, Current Pharmaceutical Design 2011; 17 (14) . https://dx.doi.org/10.2174/138161211796150855
DOI https://dx.doi.org/10.2174/138161211796150855 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Do RAS Inhibitors Protect the Brain from Cerebral Ischemic Injury?
Current Hypertension Reviews Cognitive Function and Heart Failure: The Role of the Adrenergic System
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) New Oral Antihistamines in Pediatrics and Safety of Antihistamines in Children
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents From Antidepressant Drugs to Beta-Mimetics: Preclinical Insights on Potential New Treatments for Neuropathic Pain
Recent Patents on CNS Drug Discovery (Discontinued) Cardioprotective Effects and <i>in-silico</i> Antioxidant Mechanism of L-Ergothioneine in Experimental Type-2 Diabetic Rats
Cardiovascular & Hematological Agents in Medicinal Chemistry Interplay between DNA Methyltransferase 1 and microRNAs During Tumorigenesis
Current Drug Targets The Effect of Anti-B-cell Therapy on the Development of Atherosclerosis in Patients with Rheumatoid Arthritis
Current Pharmaceutical Design Neonatal Brain Hemorrhage (NBH) of Prematurity: Translational Mechanisms of the Vascular-Neural Network
Current Medicinal Chemistry Emerging Evidence for Neurotensin Receptor 1 Antagonists as Novel Pharmaceutics in Neurodegenerative Disorders
Mini-Reviews in Medicinal Chemistry Molecule of the Month
Current Topics in Medicinal Chemistry An Overview of the Effect of Weight Loss on Cardiovascular Autonomic Function
Current Diabetes Reviews Nanowired Drug Delivery of Antioxidant Compound H-290/51 Enhances Neuroprotection in Hyperthermia-Induced Neurotoxicity
CNS & Neurological Disorders - Drug Targets Prevention of Endothelial Cell Injury by Activated Protein C: The Molecular Mechanism(s) and Therapeutic Implications
Current Vascular Pharmacology Ruta Montana Evokes Antihypertensive Activity Through an Increase of Prostaglandins Release in L-NAME-Induced Hypertensive Rats
Endocrine, Metabolic & Immune Disorders - Drug Targets Drug Delivery Systems with Modified Release for Systemic and Biophase Bioavailability
Current Clinical Pharmacology Past, Present and Future Therapeutics for Cerebellar Ataxias
Current Neuropharmacology Latest Advances in Hydrogel-Based Drug Delivery Systems for Optimization of Metabolic Syndrome Treatment
Current Medicinal Chemistry Late Life Depression: A Diagnostic and Pharmacological Review
Current Psychopharmacology Comparing the Molecular Pharmacology of CGRP and Adrenomedullin
Current Protein & Peptide Science Contribution of Catecholamine Reactive Intermediates and Oxidative Stress to the Pathologic Features of Heart Diseases
Current Medicinal Chemistry